GTX-104 + Nimodipine Capsules
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage
Conditions
Aneurysmal Subarachnoid Hemorrhage
Trial Timeline
Aug 26, 2021 → Feb 24, 2022
NCT ID
NCT05418348About GTX-104 + Nimodipine Capsules
GTX-104 + Nimodipine Capsules is a phase 1 stage product being developed by Grace Therapeutics for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT05418348. Target conditions include Aneurysmal Subarachnoid Hemorrhage.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05418348 | Phase 1 | Completed |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erythropoietin beta | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan | Idorsia | Phase 2 | 47 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 2 | 47 |
| GTX-104 + Nimotop 30 MG Oral Capsule | Grace Therapeutics | Phase 3 | 69 |